India, Feb. 4 -- Glucotrack, Inc. (GCTK), a medical technology company focused on innovative diabetes solutions, on Tuesday announced the successful completion of its first in-human clinical study for its Continuous Blood Glucose Monitor or CBGM.
This milestone study, which aimed to evaluate the safety of the implant, use, and removal of the CBGM sensor lead, confirms the potential of this novel technology.
The prospective study was conducted with six participants diagnosed with diabetes, requiring intensive insulin therapy.
The study focused on a short-term, four-day period and demonstrated the successful placement of the CBGM sensor lead, which was inserted into the subclavian vein.
It met its primary endpoint with no serious procedur...